DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) to participate in 14th Annual Craig-Hallum Alpha Select Conference in New York on November 16, 2023, offering investors the opportunity to schedule meetings with company management. Key focus on developing recombinant KLK1 (DM199) for acute ischemic stroke treatment.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be participating in the 14th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 16, 2023.

Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231109154887/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

What is DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announcing?

DiaMedica will be participating in the 14th Annual Craig-Hallum Alpha Select Conference in New York on November 16, 2023, providing an opportunity for investors to schedule meetings with company management.

What is the main focus of DiaMedica Therapeutics Inc.'s current efforts?

The company is currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke.

How can investors and attendees schedule meetings with DiaMedica's management?

They can contact their Craig-Hallum representative to arrange a meeting.